• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding universal screening for congenital cytomegalovirus (CMV) infection to Québec newborn screening program]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding the HbS/E, HbE/E and HbE/β-thal variants to the primary targets of the neonatal screening test for hemoglobinopathies]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding newborn screening for congenital adrenal hyperplasia to the Quebec newborn blood screening program]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: recommendations concerning the information required to monitor nusinersen use in real-world settings]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: RebinynTM (nonacog beta pegol) – coagulation factor IX (recombinant), notice of inclusion on the Liste des produits du système du sang du Québec]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn (nonacog beta pegol) – Type B hemophilia (re-evaluation)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Rebinyn – prophylaxis in children and adolescents with hemophilia B]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Prolastin-C Liquid – congenital alpha1-antitrypsin deficiency]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: plasma sC5b-9 assay]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: pertussis - diagnostic modalities and trajectory]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions – Part 1: Urinary incontinence]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: perineal and pelvic rehabilitation for the prevention and treatment of pelvic floor dysfunctions - Part 2: Anorectal dysfunction, pelvic organ prolapse and perineal pain in women]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: organization of the continuum and provision of services to children aged 2 to 9 years with specific language impairment]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Optune - for the treatment of adult patients with newly diagnosed glioblastoma]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optimal use of immunoglobulins in rheumatology. Report in support of the optimal use guide English summary]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optimal service trajectory for children, adolescents and young adults with attention deficit disorder with or without hyperactivity (ADHD) or related problems]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: noninvasive fetal RhD genotyping using maternal plasma]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: NK cell degranulation (natural killer)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: NGAL assay for the detection of acute kidney injury]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: microbiological stool testing in adults and children with diarrhea: relevance and measures to promote judicious use]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: KamRAB (human rabies immunoglobulin) – passive and transient postexposure prophylaxis of rabies infection]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: iStent® and iStent inject® trabecular bypass for micro-invasive glaucoma surgery (MIGS)]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: islet transplantation in patients with unstable type I diabetes]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: intensive outpatient services for youths with psychoactive substance use disorders]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: indications justifying the use of imaging for diagnosing patients with primary or secondary headache]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: immunoglobulin shortage: alternative treatments to nonspecific human immunoglobulins]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: high-dose vitamin C injections for cancer patients in Quebec]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: HemlibraMC (emicizumab) - Hemophilia A, notice of inclusion on the Liste des produits du système du sang du Québec]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Hemlibra (emicizumab) – Hemophilia A without inhibitor (re evaluation)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Glassia – congenital alpha1- antitrypsin deficiency]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: expressing wishes regarding goals of care and the decision about cardiopulmonary resuscitation]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of the relevance of newborn screening for severe combined immunodeficiency SCID]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Synvisc and Synvisc One for the management of knee osteoarthritis]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of HyQvia™ (human normal immunoglobulin 10% and hyaluronidase) – primary and secondary immunodeficiency]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Evaluation of Fibryga (human fibrinogen concentrate) – acquired fibrinogen deficiency]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Afstyla™ (rFVIII) – type A hemophilia]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Esperoct (turoctocog alfa pegol) – Hemophilia A, notice of inclusion on the Liste des produits du système du sang du Québec]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: dosing of a new generation anti-seizure panel by LC-MS/MS]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: dose banding and dose rounding of antineoplastic agents]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Cutaquig, preparation of human immunoglobulins, notice of inclusion on the Liste des produits du système du sang du Québec]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: continuous glucose monitoring system (Dexcom G6, Dexcom)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clinical utility of the different Western blot antigen profiles in the context of disseminated Lyme disease]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: circulating tumour DNA (liquid biopsy)-based EGFR exon 20 T790M mutation detection in advanced non-small cell lung cancer after previous EGFR-directed therapy]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cervical cancer screening in Québec - recommendations for implementing the human papillomavirus detection test (HPV test) as the primary screening test]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: cardiopulmonary resuscitation (CPR) in a context of community-based naloxone administration for opioid overdose]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: breast tomosynthesis and breast cancer screening]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: beta-lactam allergies, assessment of the risk of cross-reactivity with cephalosporins and carbapenems in penicillin-allergic patients]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: best strategies for reducing the risk of severe toxicities caused by dihydropyrimidine dehydrogenase deficiency]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: best practices for runaway prevention and intervention for youths living in rehabilitation centres for young persons with adjustment problems]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: benchmarks to improve services for at-risk or neglected children and their families]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: axicabtagene ciloleucel for the treatment of relapsed or refractory large B-cell lymphoma]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for argininosuccinic aciduria (ASA)]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of newborn screening for spinal muscular atrophy]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of newborn blood spot screening for biotinidase deficiency (BIOT)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of Intercept and Mirasol - pathogen reduction technologies for the treatment of labile blood products in Quebec]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of insulin pump systems for type 1 diabetes patients]
2019     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Alphanate - von Willebrand disease]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: advisability of using molecular tests to clarify the diagnosis of thyroid nodules with indeterminate cytology]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Report on the development of the GuNFT guideline. Guideline for not funding existing health technologies in health care systems]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report on optimal antipsychotic use and the nonpharmacological management of the behavioural and psychological symptoms of dementia in people with major neurocognitive disorders living in residential and long-term care centers]
2009     Andalusian Health Technology Assessment Area (AETSA) [Report NDP disinfectant (R) Med Concentrate (N-Duopropenide). Update 2008]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report and optimal usage guide: immunoglobulins in neurology]
2016     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Report adaptation: health technology assessment of the different dialysis modalities in Italy]
2009     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Repetitive Transcranial Magnetic Stimulation (rTMS)]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Repair of cartilage defects via matrix-associated autologous chondrocyte immigration]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part VIII: Budget Impact Analysis]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part VII: Options for an electronic implementation]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part VI: Health visiting services in the international context and implementation options for Austria]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part V: Preterm birth]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part IV: synthesis of parts 1-3, recommendations]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part III: Status quo of the financing and cost structures of parent-child services in Austria]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part II: international policies, approaches and screening strategies to "normal" and "risk experiences" during pregnancy and early childhood to school entry]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme. Part I: Epidemiology - incidence of risk factors and diseases in pregnancy and early childhood]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Reorientation of the Austrian parent-child preventive care programme - Part IX: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Renal sympathetic denervation for the management of resistant hypertension]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Renal sympathetic denervation as treatment of resistant hypertension]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Renal replacement therapy in advanced chronic kidney disease. Review of the starting criteria in dialysis programs and assessment of the efficacy and effectiveness of an early start]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Renal replacement therapies in acute kidney failure]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Renal denervation in patients with essential hypertonia]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Renal denervation in patients with essential hypertension]
2023     The Regional Health Technology Assessment Centre (HTA-centrum) [Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2021     Haute Autorite de sante (HAS) [Remote monitoring of patients with an implantable loop recorder]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Remote monitoring of lung function through self-administered spirometry in patients with asthma, chronic obstructive pulmonary disease or cystic fibrosis: evaluation of safety, clinical efficacy and implementation aspects]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) - benefit assessment according to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone acetate (endometriosis) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Addendum to Commission A22-108]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Relex® SMILE® surgery for refractive errors]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relevance of the condition of the opposite dentition when fitting a fixed or removable denture]
2016     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Relevance of adjusting the D-dimer test positivity threshold according to age in patients at low risk of venous thromboembolic events]